MedTrace Logo

Real-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.

NCT06190652 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 728

Last updated 2024-02-05

No results posted yet for this study

Summary

This study is a multi-center, non-interventional study. Clinicopathologic, treatment , outcome and efficacy data will be collected from medical records in metastatic esophageal squamous cell carcinoma (ESCC) patients.

Conditions

  • Metastatic Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Chemotherapy combined with immunotherapy

chemotherapy：paclitaxel+platinum-based anticancer drugs immunotherapy：anti-PD-1 Immune checkpoint inhibitors

RADIATION

radiotherapy

Intensity-modulated radiation therapy

Sponsors & Collaborators

  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER

  • Henan Cancer Hospital

    collaborator OTHER_GOV

  • Shanxi Province Cancer Hospital

    collaborator OTHER

  • Hunan Cancer Hospital

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Hebei Medical University Fourth Hospital

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Wencheng Zhang, M.D. · Tianjin Medical University Cancer Institute and Hospital

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-13
Primary Completion
2023-12-04
Completion
2023-12-04

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06190652 on ClinicalTrials.gov